SCHEMBL2956424

SCHEMBL2956424

Cc1cccc(Nc2c(C(N)=O)sc3c2ccc(=O)n3-c2ccccc2C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.39
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 5/20 0.38
HSD17B10 Q99714 3/20 0.38
NPSR1 Q6W5P4 2/20 0.38
NPC1 O15118 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
PSMD14 O00487 1/20 0.38
POLB P06746 1/20 0.38
MMP2 P08253 1/20 0.38
PTPN7 P35236 1/20 0.38
PPARG P37231 1/20 0.38
DUSP3 P51452 1/20 0.38
PTPN5 P54829 1/20 0.38
PTPN11 Q06124 1/20 0.38
NCOA2 Q15596 1/20 0.38
NCOA1 Q15788 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2949780 0.90 MAPT (0.47) CHRNA7RAB9ASMN1; SMN2KDM4EMAPT
SCHEMBL2956387 0.88 MAPT (0.43) CHRNA7RAB9ASMN1; SMN2KDM4EMAPT
SCHEMBL2958644 0.86 RAB9A (0.39) CHRNA7RAB9ASMN1; SMN2KDM4EMAPT
SCHEMBL2949616 0.83 DRD4 (0.40) CHRNA7RAB9ASMN1; SMN2KDM4EMAPT
SCHEMBL2952347 0.81 IDO1 (0.40) RAB9ASMN1; SMN2KDM4EMAPTCSF1R
SCHEMBL2959273 0.81 ALDH1A1 (0.38) SMN1; SMN2KDM4EMAPTNPSR1MEN1
SCHEMBL2956929 0.79 RAB9A (0.39) CHRNA7RAB9ASMN1; SMN2KDM4EMAPT
SCHEMBL2958459 0.79 MAPT (0.41) RAB9ASMN1; SMN2KDM4EMAPTHSD17B10
SCHEMBL2949768 0.79 MAPT (0.41) RAB9ASMN1; SMN2KDM4EMAPTHSD17B10
SCHEMBL2955910 0.79 CHRNA7 (0.44) CHRNA7MAPTRXFP1CSF1RGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US claimed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US claimed
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK CHRNA7 1817/4885RAB9A 3150/4885SMN1; SMN2 3637/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 CHRNA7 2079/4885RAB9A 2791/4885SMN1; SMN2 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.